Akamis Bio
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
245 Main St Fl 2, Cambridge, Massachuset...Phone Number
(617) 655-9767Website
www.akamisbio.comRevenue
$9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Akamis Bio
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.Explore more
Akamis Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Akamis Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Akamis Bio
Check if Akamis Bio has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Akamis Bio launches new products
Click to see if Akamis Bio had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Akamis Bio has new funding data
Earning: See what the market has to say on Akamis Bio recently announced quarterly report
Check out if Akamis Bio is spiking on competitors!
Website visits: Recent activity has been detected on your website
Akamis Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Akamis Bio
Compare insights from companies similar to Akamis Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Akamis Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Akamis Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Akamis Bio.
Akamis Bio financials insights
Gather financial insights about Akamis Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2008
Series A
$11.2M
2012
Series B
$34M
2015
Series C
$38.9M
2024
Series A
$60M
Akamis Bio Tech Stack
A closer look at the technologies used by Akamis Bio
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
Akamis Bio has secured $60 million in Series A funding. The round was led by investor Sedgwick Yard.
Funding
Open Position
Akamis Bio News & Media
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic payloads to solid tumors, today announced enrollment of the first patient in the proof-of-concept FORTRESS study of NG-350A in locally advanced rectal cancer (LARC). FORTRESS is a multi-center, open-label, non-randomized, Phase 1b study designed to measure clinical complete response (cCR) rates in patients wIn other news this week: AONIC gets €152M to design digital workplace, Akamis Bio secures ...
Here’s a brief roundup of key news you might have missed this week (from December 16th to December 20th),Akamis Bio Announces $60 Million in Funding Linked to Series A Prime Financing and New Strategic Partnership
CAMBRIDGE, Mass. & OXFORD, England--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene (T-SIGn®) therapy platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, today announced $60 million in funding linked to the close of a Series A Prime financing round and entry into a strategic partnership for the development of its lead clinical candidate, NG-350A. The new funding will suAkamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, today announced the publication of data supporting the continued clinical development and intravenous route of administration of NG-350A, its lead program for the treatment of advanced metastatic cancers. NG-350A is a next-generation tr
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Akamis Bio
Sign Up For FreeTo access detailed company insights
Akamis Bio is a clinical-stage oncology company whose mission is to leverage its groundbreaking tumor gene therapy platform to positively impact the lives of people living with cancer.... Read More
